Eye cell imaging trial with moxifloxacin drops
Part of Eyes & vision clinical trials.
This study uses a special camera to look at cells on the surface of your eye. It tests people using moxifloxacin eye drops either before eye surgery or for conditions like dry eye or Sjogren's syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You must be using or about to use 0.5% moxifloxacin eye drops for eye surgery or for a surface eye disease (like dry eye).
- You must agree to follow the study's checkups and instructions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop called PRO-240 versus Optive artificial tears in healthy adults. You will attend several visits over a few weeks and use the assigned drops as directed. The goal is to see if the new drop is as safe and comfortable as the standard one.
This study tests a new anti-inflammatory eye drop (PRO-232) in people who had routine cataract surgery on one eye the day before. The goal is to see if it helps control swelling and pain without problems.
This study uses a new imaging device called XyCAM CRE to take detailed pictures of blood vessels in the back of your eye. Researchers will compare these pictures with standard eye exam images to see if the new device works well.
This trial tests if an antibiotic injection directly into the cornea can help when standard eye drops are not working for a stubborn bacterial eye infection.
This study uses a new type of eye camera to take very detailed pictures of the front of the eye (cornea, lens, and nearby areas). It is for people with certain eye conditions or for healthy volunteers.
This trial studies whether a new, very high-resolution and high-speed eye scan can be used for people with eye problems or for healthy volunteers. It may help doctors better “see” eye structures more clearly to guide care.
Hear when a new Ocular Surface Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.